These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 8138680)
1. [Phase I study of edobacomab (E5) in patients with gram-negative sepsis]. Kobayashi H; Kawai S; Sakayori S; Endo S; Hoshi S; Inada K; Yoshida M Kansenshogaku Zasshi; 1994 Jan; 68(1):59-80. PubMed ID: 8138680 [TBL] [Abstract][Full Text] [Related]
2. [Phase II study of edobacomab (E5) in the treatment of gram-negative sepsis]. Kobayashi H; Kawai S; Sakayori S; Kaneko M; Ito Y; Ujike Y; Kobayashi K; Imaizumi H; Hoshi S; Endo S Kansenshogaku Zasshi; 1994 Jan; 68(1):81-115. PubMed ID: 8138682 [TBL] [Abstract][Full Text] [Related]
3. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238 [TBL] [Abstract][Full Text] [Related]
4. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Barriere SL; Guglielmo BJ Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812 [TBL] [Abstract][Full Text] [Related]
5. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ Crit Care Med; 1992 Jun; 20(6):730-5. PubMed ID: 1597023 [TBL] [Abstract][Full Text] [Related]
6. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody. Gorelick KJ; Chmel H Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections. Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ Prog Clin Biol Res; 1991; 367():179-86. PubMed ID: 1924426 [TBL] [Abstract][Full Text] [Related]
8. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542 [TBL] [Abstract][Full Text] [Related]
9. E5 monoclonal immunoglobulin M antibody for the treatment of gram-negative sepsis. Olsen KM; Campbell GD DICP; 1991; 25(7-8):784-90. PubMed ID: 1949940 [TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Fink MP Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494 [TBL] [Abstract][Full Text] [Related]
11. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. Angus DC; Birmingham MC; Balk RA; Scannon PJ; Collins D; Kruse JA; Graham DR; Dedhia HV; Homann S; MacIntyre N JAMA; 2000 Apr; 283(13):1723-30. PubMed ID: 10755499 [TBL] [Abstract][Full Text] [Related]
12. Anti-ovine interleukin-1beta monoclonal antibody immunotherapy in an ovine model of gram-negative septic shock. Peake SL; Pierides J; Leppard PI; Russ GR Crit Care Med; 2002 Jan; 30(1):171-81. PubMed ID: 11902259 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis. Quintiliani R; Cooper B; Maderazo E; Nightingale C Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116 [TBL] [Abstract][Full Text] [Related]
14. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Calandra T; Baumgartner JD; Glauser MP Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to endotoxin in the management of sepsis. Fang KC West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic and clinical studies with cefluprenam in the pediatric field. Pediatric Study Group of Gefluprenam]. Fujii R; Abe T; Tajima T; Kobayashi M; Terashima I; Meguro H; Sunakawa K; Yokota T; Akita H; Kusumoto Y; Iwata S; Satoh Y; Toyonaga Y; Ishihara T; Nakamura H; Iwai N; Nakamura H; Kuno K; Katoh T; Ogawa A; Itomi K; Okumura A; Hayakawa F; Takahashi H; Etoh M Jpn J Antibiot; 1997 Jul; 50(7):597-621. PubMed ID: 9743906 [TBL] [Abstract][Full Text] [Related]
17. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827 [TBL] [Abstract][Full Text] [Related]
18. Role of immunomodulator therapy in sepsis. Caplan ES Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996 [TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibody against endotoxin. Zarowitz BJ DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock. Baumgartner JD Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):711-6. PubMed ID: 2261915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]